ESSA Pharma to be Acquired by XenoTherapeutics in All-Cash Deal
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) has provided an announcement.
ESSA Pharma Inc. has entered into a definitive agreement to be acquired by XenoTherapeutics, Inc., with financial backing from XOMA Royalty Corporation. This acquisition will provide ESSA shareholders with a cash payment per share, determined by the company’s cash balance at closing, and a contingent value right. The transaction is part of ESSA’s plan to discontinue operations and wind down its business, offering shareholders expedited cash value with reduced complexity compared to liquidation. The deal requires approval from ESSA securityholders and is expected to close in the second half of 2025.
The most recent analyst rating on (EPIX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. operates in the biotechnology industry, focusing on developing therapies for the treatment of cancer, particularly prostate cancer. The company is known for its innovative approach in targeting the androgen receptor pathway, which is crucial in the progression of prostate cancer.
Average Trading Volume: 237,960
Technical Sentiment Signal: Sell
Current Market Cap: $82.56M
See more insights into EPIX stock on TipRanks’ Stock Analysis page.
